APHINITY Data: Perjeta Cuts Death Risk by 17% in HER2+ Breast Cancer
– Long term follow-up in this curative setting demonstrated clinically meaningful survival benefit when adding adjuvant Perjeta® (pertuzumab) to Herceptin® (trastuzumab) and chemotherapy – – 21% reduction in...